Mobile Site ›

Warfarin Sensitivity Genotyping



Genotype-guided Dosing

Slide 20

August 2008

When using genotype guided dosing, you can explain all but about 32% of dosing variability if you consider co-medications, non-genetic factors such as age, weight and also the genotypes for the CYP2C9 and the VKORC1 alleles. This is in contrast to how we currently do this where we look at weight, age and co-medications where roughly 70% of dosing variability has to be dealt with empirically.

Genotype-guided Dosing

 


Jump to section:


Key